{"gene":"SOST","run_date":"2026-06-10T07:46:38","timeline":{"discoveries":[{"year":2001,"finding":"Loss-of-function mutations in the SOST gene (nonsense and splice site mutations) cause sclerosteosis, establishing that the SOST protein product (sclerostin) is a secreted negative regulator of bone formation. The protein contains a signal peptide and a cysteine-knot motif, placing it in the DAN family of cystine knot-containing factors.","method":"Positional cloning, mutation analysis in sclerosteosis patients, protein domain analysis","journal":"Human molecular genetics / American journal of human genetics","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — independently replicated by two groups (PMID:11181578 and PMID:11179006) using positional cloning and mutation identification in affected families","pmids":["11181578","11179006"],"is_preprint":false},{"year":2002,"finding":"Van Buchem disease is caused by a 52-kb deletion located ~35 kb downstream of the SOST gene (not within its coding region), establishing that this non-coding region contains a cis-regulatory element essential for SOST transcription in bone.","method":"Linkage analysis, deletion mapping, haplotype analysis in van Buchem families","journal":"Journal of medical genetics / American journal of medical genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — independently identified by two groups (PMID:11836356 and PMID:12116252) using genetic mapping and deletion characterization","pmids":["11836356","12116252"],"is_preprint":false},{"year":2005,"finding":"SOST/sclerostin antagonizes Wnt signaling by directly binding to the extracellular domain of the Wnt co-receptors LRP5 and LRP6, disrupting Wnt-induced Frizzled-LRP complex formation.","method":"Binding assays (LRP5/LRP6 extracellular domain binding), Xenopus embryo Wnt antagonism assay, mammalian cell Wnt reporter assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding demonstrated in multiple systems (Xenopus and mammalian cells) with functional Wnt inhibition readout; replicated by subsequent LRP5 HBM mutation study (PMID:17052975)","pmids":["15908424"],"is_preprint":false},{"year":2006,"finding":"LRP5 high bone mass (HBM) mutations cluster in the extracellular domain and reduce LRP5 binding to SOST, rendering LRP5 more refractory to inhibition by sclerostin, mechanistically linking SOST-LRP5 antagonism to bone mass regulation.","method":"Binding assays comparing SOST interaction with wild-type vs. HBM mutant LRP5 proteins, functional Wnt inhibition assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding measurements with multiple mutants, consistent with prior SOST-LRP5 binding data","pmids":["17052975"],"is_preprint":false},{"year":2005,"finding":"PTH directly suppresses SOST transcription in vivo and in vitro via the cAMP/PKA pathway; the effect is not blocked by cycloheximide (indicating direct transcriptional regulation) and PTH does not alter SOST mRNA stability, pointing to transcriptional rather than post-transcriptional control.","method":"In vivo PTH administration (calvarial, systemic, intermittent) + qPCR; in vitro UMR-106 cell treatment with PTH, PKA/PKC pathway inhibitors/activators, cycloheximide, and PTH antagonist","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo and in vitro models, pharmacological dissection of signaling pathway, replicated across multiple labs in subsequent papers","pmids":["15946907"],"is_preprint":false},{"year":2007,"finding":"MEF2 transcription factors (MEF2A, MEF2C, MEF2D) bind a MEF2 response element in the SOST bone enhancer (within the 52-kb van Buchem deletion) to activate SOST transcription in osteocytes; PTH suppresses SOST by inhibiting this MEF2-dependent enhancer activity rather than the SOST promoter.","method":"Luciferase reporter assays, footprint/mutation analysis, gel retardation (EMSA), antibody supershift, siRNA knockdown of MEF2 isoforms, ISH/IHC co-localization in bone","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — multiple orthogonal methods (EMSA, reporter, siRNA) in a single focused study with rigorous controls","pmids":["17696759"],"is_preprint":false},{"year":2007,"finding":"Mechanical loading (ulnar loading) dramatically reduces Sost mRNA and sclerostin protein in osteocytes in a strain-magnitude-dependent manner, while hindlimb unloading increases Sost expression, establishing osteocyte-expressed sclerostin as a mechanically regulated bone formation inhibitor.","method":"In vivo ulnar loading and hindlimb unloading models; ISH (Sost mRNA) and IHC (sclerostin protein) in mouse tibia/ulna","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — two complementary mechanical models with both mRNA and protein readouts; widely replicated by subsequent studies","pmids":["18089564"],"is_preprint":false},{"year":2011,"finding":"Sost downregulation in osteocytes is an obligatory step in the mechanotransduction cascade: transgenic mice engineered to maintain high SOST expression during loading showed 70-85% reduction in load-induced bone formation and absence of Wnt target gene induction, demonstrating that sclerostin suppression is required to unleash local Wnt signaling for osteogenesis.","method":"In vivo ulnar loading in SOST-transgenic mice (DMP1-driven human SOST transgene) vs. wild-type; bone formation histomorphometry; Wnt target gene qPCR","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic gain-of-function model with direct epistasis test, multiple orthogonal readouts (histomorphometry + gene expression)","pmids":["22075208"],"is_preprint":false},{"year":2004,"finding":"RUNX2/Cbfa1 binds the proximal SOST promoter and contributes to differential SOST expression in osteosarcoma cells, and an E-box binding motif in the 1.8-kb proximal SOST promoter is also functional in SAOS-2 cells.","method":"Gel shift (EMSA), transient transfection luciferase assays in osteosarcoma cell lines","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — EMSA and reporter assays in a single study, single lab","pmids":["14739291"],"is_preprint":false},{"year":2004,"finding":"BMP-2, BMP-4, and BMP-6 induce SOST expression in human osteoblasts in a time- and dose-dependent manner; this effect is enhanced by retinoic acid and 1,25-dihydroxyvitamin D3, but blocked by dexamethasone. This regulation differs from other BMP antagonists (noggin, gremlin), indicating unique upstream control of SOST.","method":"RT-PCR/Northern analysis in human osteoblast cultures treated with BMPs, steroids, and growth factors","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — mRNA expression assays in multiple treatment conditions, replicated directionally in subsequent studies (PMID:19874086, PMID:21945937)","pmids":["15268896"],"is_preprint":false},{"year":2010,"finding":"BMP signaling through BMPRIA in osteoblasts positively regulates Sost and Dkk1 expression: conditional knockout of Bmpr1a in osteoblasts reduces Sost and Dkk1 levels and increases Wnt/β-catenin signaling; BMP2 upregulates and Noggin downregulates both inhibitors; BMP2-induced Dkk1 (but not Sost) is blocked by p38 MAPK inhibition, indicating differential downstream signaling.","method":"Conditional knockout mice (Bmpr1a cKO), Wnt reporter assays (TOPGAL, TOPFLASH), BMP2/Noggin/dorsomorphin treatment, SB202190 inhibitor; qPCR","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO combined with pharmacological tools and multiple Wnt reporter readouts, single lab but multiple orthogonal approaches","pmids":["19874086"],"is_preprint":false},{"year":2011,"finding":"Loss of ACVR1 (BMP receptor for BMP7) specifically in osteoblasts increases bone mass and suppresses expression of both Sost and Dkk1, activating canonical Wnt signaling; BMP7 dose-dependently upregulates Sost and Dkk1 in vitro, defining a BMP7-ACVR1-SOST/DKK1 axis.","method":"Inducible osteoblast-specific Acvr1 conditional KO mice, qPCR, in vitro BMP7 treatment of osteoblasts","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic KO model with gene expression validation, single lab, limited mechanistic depth","pmids":["21945937"],"is_preprint":false},{"year":2011,"finding":"Sirt1 directly represses Sost gene expression by deacetylating histone 3 at lysine 9 at the Sost promoter, as demonstrated by chromatin immunoprecipitation; Sirt1 haploinsufficiency increases sclerostin levels and reduces bone formation.","method":"ChIP analysis in Sirt1+/- mice; siRNA knockdown of Sost; sclerostin-neutralizing antibody rescue experiments; osteocalcin/bone sialoprotein gene expression and mineralization assays","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP showing direct histone deacetylation at Sost promoter, functional rescue experiments; single lab","pmids":["21952235"],"is_preprint":false},{"year":2011,"finding":"Strain-induced Sost downregulation in human osteoblastic cells (Saos2) is mediated by COX-2-dependent prostaglandin E2 (PGE2) acting through the EP4 receptor and requires ERK signaling; strain-induced osteocalcin upregulation uses the EP2 receptor and PKC, demonstrating early pathway divergence.","method":"Dynamic strain of Saos2 cells; COX-2 inhibitors; EP receptor agonists/antagonists; MEK/ERK inhibitors; qRT-PCR","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological dissection in a cell line with multiple pathway inhibitors, single lab","pmids":["21723865"],"is_preprint":false},{"year":2013,"finding":"Estrogen receptor β (ERβ), not ERα, mediates the acute down-regulation of Sost expression by mechanical strain and estradiol in osteoblastic cells; ERβ agonists recapitulate Sost suppression, ERβ antagonist or ERβ deletion prevents it, and the effect requires MEK/ERK signaling.","method":"ERα/ERβ selective agonists/antagonists in mouse long bone osteoblasts and Saos-2 cells; in vivo ERα-null mouse; ERβ-null osteoblasts; MEK/ERK inhibitors; qPCR","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal pharmacological and genetic approaches in vitro and in vivo, single lab","pmids":["23362266"],"is_preprint":false},{"year":2013,"finding":"HIF-1α transcriptionally activates Sost expression in osteoblasts under hypoxia by directly binding a hypoxia response element in the Sost promoter (within the −260 bp minimal region); HIF-1α siRNA reduces Sost expression; DFO (HIF-1α activator) further increases Sost.","method":"qRT-PCR; siRNA knockdown of HIF-1α; deletion mutant Sost promoter-luciferase reporters; gel shift (EMSA); DFO treatment of osteoblasts","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1-2 / Weak — promoter deletion analysis, EMSA, and siRNA in a single study; single lab","pmids":["23776575"],"is_preprint":false},{"year":2011,"finding":"Signal peptide mutations (Val21Met, Val21Leu) in the SOST gene cause autosomal dominant craniodiaphyseal dysplasia by dramatically reducing SOST secretion, acting through a dominant negative mechanism distinct from the recessive loss-of-function mutations causing sclerosteosis/van Buchem disease.","method":"Transfection of mutant SOST constructs into 293E cells; secretion assay","journal":"Human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — direct secretion assay with mutant constructs, single study with clear functional readout","pmids":["21221996"],"is_preprint":false},{"year":2010,"finding":"The missense mutation p.Cys167Arg in the SOST cystine-knot motif causes retention of mutant sclerostin in the ER (impaired folding/secretion) and significantly reduces LRP5 binding and Wnt signaling inhibition, establishing that the cystine-knot integrity is required for sclerostin's secretion and function.","method":"Functional assays: LRP5 binding assay, Wnt signaling reporter assay, ER retention/secretion assay in transfected cells","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — multiple functional approaches (binding, Wnt reporter, secretion) in a single study; single lab","pmids":["20583295"],"is_preprint":false},{"year":2014,"finding":"Sost deficiency-induced bone anabolism partially requires LRP5, but fully depends on Wnt1 class-induced LRP6 activity: selective blockade of Wnt1-class LRP6 signaling completely reversed bone overgrowth in Sost-/- and Sost-/-;Lrp5-/- mice to wild-type levels.","method":"Sost-/-;Lrp5-/- double knockout mice; treatment with class-selective anti-LRP6 antibodies; microCT and histomorphometry","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (double KO) combined with pharmacological LRP6 antibody intervention, multiple skeletal parameters measured","pmids":["23901037"],"is_preprint":false},{"year":2013,"finding":"DNA methylation of the SOST promoter CpG region regulates SOST expression in osteoarthritic chondrocytes; BMP-2 increases SOST expression via Smad1/5/8 binding to the hypomethylated CpG region of the SOST promoter, as shown by ChIP; 5-AzadC (demethylation) increases SOST expression.","method":"Methylation-specific PCR, bisulfite sequencing, 5-AzadC treatment, ChIP for Smad1/5/8 binding, qRT-PCR and Western blot in OA chondrocytes","journal":"Arthritis research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — ChIP plus epigenetic manipulation, single lab, limited mechanistic depth","pmids":["26071314"],"is_preprint":false},{"year":2015,"finding":"LRP6 is required for PTH-induced suppression of Sost in osteocytes: osteoblast-specific Lrp6 KO mice show elevated Sost/sclerostin levels and blunted PTH-induced Sost suppression; PTH-induced downregulation of MEF2C/D and HDAC changes in osteocytes were abrogated in LRP6-KO mice.","method":"Osteoblast-specific Lrp6-KO mice; intermittent PTH treatment; qPCR for Sost; IHC for sclerostin+ osteocytes; MEF2 and HDAC protein analysis","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — genetic KO model with PTH challenge, multiple molecular readouts; single lab","pmids":["25847683"],"is_preprint":false},{"year":2016,"finding":"N-cadherin restrains PTH-mediated suppression of sclerostin/SOST by reducing LRP6-PTH1R interaction and endocytosis; overexpression of N-cadherin blunts PTH-induced downregulation of MEF2A/C/D and SOST; osteocyte-specific N-cadherin deletion (Cdh2ΔDmp1) accentuates iPTH-induced SOST suppression and enhances PTH bone anabolic effects.","method":"N-cadherin overexpression in vitro; osteocyte-specific Cdh2 KO (Dmp1-Cre) mice; iPTH treatment; LRP6-PTHR1 co-IP/endocytosis; qPCR; immunoblot","journal":"Annals of the New York Academy of Sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro overexpression and in vivo genetic model with multiple mechanistic readouts; single lab","pmids":["27723935"],"is_preprint":false},{"year":2019,"finding":"Mechanical stretch-induced suppression of Sost expression in osteocytes (IDG-SW3 cells) is mediated by the mechanosensitive ion channel Piezo1 and requires downstream Akt activation; Piezo1 agonist (Yoda1) decreases Sost expression, and this is abrogated by Piezo1 inhibitor GsMTx4, Piezo1 deficiency, or Akt inhibition.","method":"IDG-SW3 osteocyte cell line; Yoda1 treatment; mechanical stretch; GsMTx4 (Piezo1 inhibitor); Piezo1 siRNA/knockout; Akt inhibitor; qPCR for Sost; intracellular calcium imaging","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic loss-of-function of Piezo1, plus kinase inhibition, multiple orthogonal approaches in a single study","pmids":["31708103"],"is_preprint":false},{"year":2009,"finding":"The matricellular protein periostin (Postn) is required for mechanical stimulation-induced inhibition of Sost in bone; Postn-/- mice have elevated baseline Sost expression that is unresponsive to exercise/loading, and sclerostin-blocking antibody rescues the impaired bone biomechanical response in these mice.","method":"Postn-/- mice; exercise and axial tibial compression models; anti-sclerostin antibody rescue; bone microarchitecture and biomechanics; gene expression (Sost, periostin)","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model, mechanical challenge, and antibody rescue; multiple readouts; single lab","pmids":["19837663"],"is_preprint":false},{"year":2013,"finding":"Nitric oxide (NO) is involved in pulsating fluid flow (PFF)-induced downregulation of SOST expression in human bone cells; NOS inhibitor 1400W prevents the PFF effect on SOST; NO donor SNAP decreases SOST mRNA; conditioned medium from PFF-stimulated cells decreases SOST promoter transcriptional activity, indicating secreted factors also contribute.","method":"Pulsating fluid flow on AzadC-treated human bone cells; NOS inhibitor (1400W); NO donor (SNAP); SOST promoter-reporter assay; conditioned medium transfer","journal":"Calcified tissue international","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological NOS inhibition and NO donor, promoter reporter, conditioned medium assay; single lab","pmids":["24322886"],"is_preprint":false},{"year":2015,"finding":"PIGMENT EPITHELIUM DERIVED FACTOR (PEDF) suppresses Sost/sclerostin expression by 70% in mineralizing osteoblast cultures and by 50% in primary osteocytes, leading to increased total β-catenin (Wnt signaling activation) and enhanced mineralization.","method":"Exogenous PEDF treatment of mineralizing human osteoblast cultures and primary osteocytes; qRT-PCR; Western blot; immunoprecipitation; β-catenin assay","journal":"Journal of cellular physiology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single-method expression assays and western blot; mechanism upstream of PEDF-SOST link not fully defined; single lab","pmids":["25363869"],"is_preprint":false},{"year":2018,"finding":"Sclerostin (SOST) inhibits MMP2/3 expression and activity after joint injury; SOST transgenic mice develop less severe PTOA and osteophytes, with ~2-fold less MMP activation; intra-articular recombinant Sost protein post-injury decreases MMP activity; Sost induction in response to joint injury is TNFα and NF-κB dependent.","method":"SOST transgenic and Sost-/- mice; noninvasive tibial compression overload PTOA model; MMP activity quantification; MMP2/3 protein measurement; recombinant Sost intra-articular injection; TNFα and NF-κB pathway analysis","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic gain-of-function and KO loss-of-function plus recombinant protein rescue; multiple orthogonal readouts; single lab","pmids":["29377313"],"is_preprint":false},{"year":2007,"finding":"SOST is expressed in the medial vessel wall smooth muscle cells of the great arteries (ascending aorta, aortic arch, brachiocephalic, common carotids, pulmonary trunk) from embryonic day 15.5 to neonatal period, but its expression does not correspond with inhibition of Smad-dependent BMP or β-catenin-dependent Wnt activity in these vessels.","method":"In situ hybridization and IHC for SOST/sclerostin; BMP signaling (pSmad) and Wnt (β-catenin) reporter/IHC in mouse embryo cardiovascular tissue sections","journal":"Developmental dynamics","confidence":"Low","confidence_rationale":"Tier 3 / Weak — localization by ISH/IHC with negative functional correlation; no direct functional experiment on SOST in vasculature","pmids":["17195180"],"is_preprint":false},{"year":2015,"finding":"The human SOST gene is directly and positively regulated by 1α,25-dihydroxyvitamin D3 (1,25D) in osteocyte-like SaOS2 cells, mediated at least in part by a DR3-type vitamin D response element; SOST mRNA and sclerostin protein increase within 3 hours of 1,25D treatment and decrease within 3 hours of PTH treatment.","method":"1,25D and PTH treatment of differentiated SaOS2 osteocyte-like cells; qRT-PCR and protein measurement at early time points; CYP24A1 induction assay","journal":"The Journal of steroid biochemistry and molecular biology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — mRNA and protein expression assays, functional VDRE implied but not fully characterized; single lab, cell line only","pmids":["26690786"],"is_preprint":false},{"year":2015,"finding":"Compressive force upregulates SOST (and POSTN) expression in human PDL fibroblasts via TGF-β1: cycloheximide, TGF-β inhibitor (SB431542), or TGF-β1 neutralizing antibody attenuate force-induced SOST and POSTN expression; TGF-β1 accumulates intracellularly/in matrix (not in medium) in response to force.","method":"Computer-controlled compressive force loading apparatus on hPDL cells; qRT-PCR; Western blot; cycloheximide; TGF-β receptor inhibitor; neutralizing antibody; ELISA for TGF-β1","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological and antibody blockade of TGF-β pathway; single lab; limited depth","pmids":["25870205"],"is_preprint":false},{"year":2017,"finding":"Notch signaling participates in TGF-β-induced SOST expression in human PDL cells under compressive stress: compressive force induces NOTCH2, NOTCH3, HES1, HEY1; γ-secretase inhibitor (DAPT) reduces stress-induced SOST; TGF-β receptor inhibitor reduces Notch activation; recombinant TGF-β1 enhances SOST and Notch gene expression, and DAPT attenuates TGF-β1-induced SOST.","method":"Intermittent compressive stress apparatus on hPDL cells; TGF-β receptor inhibitor (SB431542); γ-secretase inhibitor (DAPT); recombinant TGF-β1; qPCR; Western blot","journal":"Journal of cellular physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — pharmacological pathway inhibition showing sequential TGF-β/Notch/SOST axis; single lab","pmids":["27966788"],"is_preprint":false},{"year":2018,"finding":"Osteocyte-derived sclerostin impairs osteogenesis and angiogenesis via inhibiting the Wnt pathway; co-culture of osteocytes with MC3T3-E1 or endothelial cells in the presence of dexamethasone worsened inhibition, and SOST-silencing of osteocytes rescued these effects; in vivo SOST KO ameliorated glucocorticoid-associated osteonecrosis of femoral head.","method":"Co-culture of Ocy454 osteocytes (± SOST silencing) with MC3T3-E1 and endothelial cells + dexamethasone; SOST KO rat GA-ONFH model; histology, IHC, bone metabolic markers","journal":"Molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — co-culture mechanistic model plus in vivo KO; single lab; mechanism (Wnt pathway inhibition) inferred from pathway markers","pmids":["39342093"],"is_preprint":false},{"year":2018,"finding":"Osteocyte Dmp1-Cre-specific deletion of Bmpr1a reduces Sost mRNA in bone by >95% and serum SOST protein by ~85%, activates Wnt/β-catenin signaling, and also dramatically decreases RANKL while increasing OPG, leading to osteosclerosis—establishing that BMP signaling through BMPR1A in osteocytes positively regulates Sost expression.","method":"Dmp1-Cre conditional Bmpr1a KO mice; microCT; histomorphometry; qPCR; ELISA for serum SOST and RANKL; β-catenin/Tcf target gene expression; mechanical testing","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 / Strong — osteocyte-specific genetic KO with comprehensive molecular, cellular and structural phenotyping; multiple orthogonal readouts","pmids":["27402532"],"is_preprint":false},{"year":2022,"finding":"SOST interacts with STAT3 to enhance TGF-β/KRAS signaling in breast cancer cells, increasing tumor growth and bone metastasis; SOST silencing reduces bone metastatic capacity of SCP2 cells; small molecule S6 inhibiting SOST-STAT3 interaction suppresses breast cancer growth and bone metastasis in vivo.","method":"Co-IP (SOST-STAT3 interaction); SOST silencing/overexpression in SCP2 cells; in vitro and in vivo bone metastasis assays; small molecule screen; breast cancer organoid treatment","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Weak — Co-IP for SOST-STAT3 binding plus in vivo functional studies; single lab; novel context (cancer) requires further validation","pmids":["36581888"],"is_preprint":false},{"year":2013,"finding":"Sost and its paralog Sostdc1 coordinately regulate digit number: in the developing limb, Sost is restricted to distal ectoderm and Sostdc1 to proximal ectoderm/mesenchyme; Sost-/-;Sostdc1-/- double KO mice show elevated Wnt signaling leading to misregulation of SHH signaling, ectopic Sox9 activation, and preaxial polydactyly in a Gli1/Gli3-dependent manner; syndactyly in Sost-/- is driven by misregulation of Fgf8 in the AER.","method":"Sost-/-, Sostdc1-/-, and double KO mice; limb phenotype analysis; Shh/Gli signaling analysis; ISH; epistasis with Gli1/Gli3 mutants","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic models with pathway epistasis analysis; single lab","pmids":["23994639"],"is_preprint":false},{"year":2018,"finding":"Multiple osteoblast lineage cell types contribute paracrine sclerostin to the bone microenvironment: conditional deletion of Sost in Prx1 (osteoprogenitor), Col1 (midstage osteoblast), Dmp1 (mature osteocyte), and ColX (hypertrophic chondrocyte) lineages all increased trabecular bone mass; only Prx1-Cre deletion fully recapitulated the full HBM phenotype and the B-cell defect of global Sost KO. Sclerostin from axial skeleton does not influence appendicular bone in a circulating endocrine manner.","method":"Cell type-specific conditional Sost KO mice (4 Cre lines); microCT; DXA; cortical bone histomorphometry; B-cell FACS analysis","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — four independent conditional KO models enabling dissection of cell-type contributions and paracrine vs. endocrine action; single lab with comprehensive phenotyping","pmids":["29750826"],"is_preprint":false}],"current_model":"Sclerostin (SOST) is a secreted cystine-knot glycoprotein produced predominantly by osteocytes that inhibits bone formation by directly binding to the extracellular domain of the Wnt co-receptors LRP5 and LRP6, disrupting Frizzled-LRP complex formation and suppressing canonical Wnt/β-catenin signaling; its transcription in osteocytes is driven by MEF2 transcription factors acting on a bone-specific enhancer ~35 kb downstream of the gene, is positively regulated by BMP signaling through BMPRIA/ACVR1, and is suppressed by mechanical loading (via Piezo1-Akt and PGE2/EP4-ERK pathways), PTH (via cAMP/PKA-MEF2 axis requiring LRP6), Sirt1 (via histone H3K9 deacetylation), and estrogen receptor β; loss-of-function mutations in SOST cause sclerosteosis/van Buchem disease due to unopposed Wnt signaling and consequent bone overgrowth."},"narrative":{"mechanistic_narrative":"Sclerostin (SOST) is a secreted cystine-knot glycoprotein produced predominantly by osteocytes and osteoblast-lineage cells that acts as a paracrine negative regulator of bone formation [PMID:11181578, PMID:11179006, PMID:29750826]. It functions by directly binding the extracellular domains of the Wnt co-receptors LRP5 and LRP6, disrupting Wnt-induced Frizzled-LRP complex formation and thereby suppressing canonical Wnt/β-catenin signaling [PMID:15908424]; high-bone-mass LRP5 mutations that weaken this interaction render the receptor refractory to sclerostin inhibition [PMID:17052975], and Sost-deficiency-driven bone anabolism depends partially on LRP5 but fully on Wnt1-class LRP6 activity [PMID:23901037]. Integrity of the cystine-knot motif and an intact signal peptide are required for sclerostin folding, secretion, and LRP5 binding [PMID:21221996, PMID:20583295]. SOST transcription in osteocytes is controlled through a bone-specific enhancer ~35 kb downstream of the gene, where MEF2 transcription factors (MEF2A/C/D) drive expression [PMID:17696759]; this enhancer region is the element deleted in van Buchem disease [PMID:11836356, PMID:12116252]. SOST is positively regulated by BMP signaling acting through osteoblast/osteocyte BMPRIA and ACVR1 receptors [PMID:19874086, PMID:21945937, PMID:27402532] and is suppressed by mechanical loading and by PTH, the latter via a cAMP/PKA pathway that targets the MEF2-dependent enhancer rather than the promoter [PMID:15946907, PMID:17696759, PMID:18089564]. Mechanically induced suppression of SOST is an obligatory step in load-induced osteogenesis: forced maintenance of SOST during loading abolishes the Wnt-driven bone formation response [PMID:22075208], and is transduced via the mechanosensitive channel Piezo1–Akt axis, COX-2/PGE2–EP4–ERK signaling, estrogen receptor β, periostin, and nitric oxide [PMID:31708103, PMID:21723865, PMID:23362266, PMID:19837663, PMID:24322886]. Recessive loss-of-function SOST mutations cause sclerosteosis and van Buchem disease through unopposed Wnt signaling and bone overgrowth, while dominant-negative signal-peptide mutations that block secretion cause craniodiaphyseal dysplasia [PMID:11181578, PMID:11179006, PMID:11836356, PMID:12116252, PMID:21221996]. Beyond bone, SOST has been implicated in limb digit patterning together with its paralog Sostdc1 [PMID:23994639] and in breast cancer bone metastasis via a STAT3 interaction [PMID:36581888].","teleology":[{"year":2001,"claim":"Establishing that SOST encodes a secreted bone-formation inhibitor answered what gene underlies sclerosteosis and placed sclerostin in the cystine-knot factor family.","evidence":"Positional cloning and mutation analysis in sclerosteosis families with protein domain analysis","pmids":["11181578","11179006"],"confidence":"High","gaps":["Molecular target of secreted sclerostin not yet identified","Cell of origin within bone not yet defined"]},{"year":2002,"claim":"Mapping van Buchem disease to a downstream non-coding deletion revealed that a distant cis-regulatory element, not the coding sequence, governs SOST expression in bone.","evidence":"Linkage analysis and deletion mapping in van Buchem families","pmids":["11836356","12116252"],"confidence":"High","gaps":["Identity of the transcription factors acting on the enhancer not yet known","Tissue specificity of the element not yet dissected"]},{"year":2005,"claim":"Demonstrating direct binding of sclerostin to LRP5/LRP6 defined the molecular mechanism by which SOST inhibits bone formation—antagonism of canonical Wnt signaling.","evidence":"LRP extracellular-domain binding assays plus Xenopus and mammalian Wnt reporter assays","pmids":["15908424"],"confidence":"High","gaps":["Relative contributions of LRP5 vs LRP6 in vivo not resolved","Structural basis of binding not determined"]},{"year":2006,"claim":"Showing that LRP5 high-bone-mass mutations reduce sclerostin binding mechanistically linked the SOST-LRP5 interaction directly to bone mass set-point.","evidence":"Binding and Wnt-inhibition assays comparing wild-type vs HBM mutant LRP5","pmids":["17052975"],"confidence":"High","gaps":["Did not address LRP6 contribution","In vivo consequences of altered binding inferred not measured"]},{"year":2005,"claim":"Identifying that PTH suppresses SOST transcription via cAMP/PKA, independent of protein synthesis, established hormonal control of sclerostin as direct and transcriptional.","evidence":"In vivo PTH administration plus UMR-106 cell pharmacology with cycloheximide and PKA modulators","pmids":["15946907"],"confidence":"High","gaps":["Transcription factor target downstream of PKA not identified in this study","Specific cis-element not localized here"]},{"year":2007,"claim":"Localizing MEF2 binding to the downstream bone enhancer connected the van Buchem regulatory region to its transcription factors and revealed PTH acts on the enhancer rather than the promoter.","evidence":"EMSA, reporter assays, siRNA knockdown of MEF2 isoforms, and bone co-localization","pmids":["17696759"],"confidence":"High","gaps":["Upstream signals coupling PTH/PKA to MEF2 inactivation not fully defined","Chromatin context of enhancer not characterized"]},{"year":2007,"claim":"Showing that mechanical loading reduces and unloading increases osteocyte sclerostin established SOST as a strain-responsive regulator of bone formation.","evidence":"In vivo ulnar loading and hindlimb unloading with Sost mRNA and protein readouts","pmids":["18089564"],"confidence":"High","gaps":["Mechanotransduction pathway upstream of Sost not yet identified","Whether suppression is required for osteogenesis not yet tested"]},{"year":2011,"claim":"Engineering persistent SOST during loading proved that sclerostin downregulation is an obligatory step for load-induced Wnt activation and bone formation.","evidence":"Ulnar loading of DMP1-driven SOST-transgenic mice with histomorphometry and Wnt target qPCR","pmids":["22075208"],"confidence":"High","gaps":["Sensors and intermediate signaling not addressed in this model","Residual bone formation source not defined"]},{"year":2010,"claim":"Genetic and pharmacological dissection of BMP receptors established that BMP signaling through BMPRIA and ACVR1 positively regulates Sost expression, with osteocyte BMPR1A deletion nearly abolishing Sost.","evidence":"Conditional Bmpr1a and Acvr1 knockouts, BMP/Noggin treatment, Wnt reporters, and serum SOST ELISA","pmids":["19874086","21945937","27402532"],"confidence":"High","gaps":["Direct BMP-responsive cis-elements in SOST not fully mapped in osteocytes","Differential downstream signaling for Sost vs Dkk1 partially characterized"]},{"year":2013,"claim":"Double-knockout and class-selective LRP6 antibody experiments resolved that Sost-deficiency anabolism depends only partially on LRP5 but fully on Wnt1-class LRP6 signaling.","evidence":"Sost-/-;Lrp5-/- mice with anti-LRP6 antibodies, microCT and histomorphometry","pmids":["23901037"],"confidence":"High","gaps":["Ligand source for Wnt1-class signaling in bone not defined","Molecular reason for LRP6 dominance not established"]},{"year":2019,"claim":"Identifying Piezo1, PGE2/EP4-ERK, ERβ, periostin, and nitric oxide as mediators progressively mapped the mechanotransduction cascade that suppresses SOST in osteocytes.","evidence":"Pharmacological and genetic loss-of-function across osteocyte cell lines and loading/fluid-flow models","pmids":["31708103","21723865","23362266","19837663","24322886"],"confidence":"Medium","gaps":["How these inputs converge on the MEF2 enhancer not integrated","Relative contribution of each pathway in vivo unclear"]},{"year":2016,"claim":"Defining the LRP6-dependent, N-cadherin-modulated PTH-PTH1R axis showed how PTH-induced SOST suppression is mechanistically wired in osteocytes.","evidence":"Osteoblast/osteocyte-specific Lrp6 and Cdh2 knockouts with iPTH challenge and LRP6-PTHR1 co-IP","pmids":["25847683","27723935"],"confidence":"Medium","gaps":["Precise step where LRP6 couples to MEF2/HDAC regulation not resolved","Single-lab findings on N-cadherin modulation"]},{"year":2013,"claim":"Promoter-level studies extended SOST regulation to additional transcription factors and epigenetic inputs (RUNX2, Sirt1/H3K9 deacetylation, HIF-1α, DNA methylation, vitamin D).","evidence":"EMSA, ChIP, promoter-reporter, siRNA, and methylation analyses across osteosarcoma, osteocyte, and chondrocyte models","pmids":["14739291","21952235","23776575","26071314","26690786"],"confidence":"Medium","gaps":["Many findings are single-lab and cell-line based","Integration with the dominant downstream enhancer not established"]},{"year":2011,"claim":"Functional analysis of secretion-defective mutants distinguished dominant-negative craniodiaphyseal dysplasia mutations from recessive loss-of-function alleles and established cystine-knot requirement for secretion and LRP5 binding.","evidence":"Transfection secretion assays, ER-retention, LRP5 binding and Wnt reporter assays for signal-peptide and Cys167Arg mutants","pmids":["21221996","20583295"],"confidence":"Medium","gaps":["Dominant-negative mechanism on wild-type secretion not fully characterized","Single-study functional data"]},{"year":2018,"claim":"Cell-type-specific deletions established sclerostin's paracrine, non-endocrine mode of action and identified multiple osteoblast-lineage sources contributing to the bone microenvironment.","evidence":"Four Cre-driven conditional Sost knockouts with microCT, DXA, histomorphometry, and B-cell FACS","pmids":["29750826"],"confidence":"High","gaps":["Molecular basis of paracrine vs endocrine restriction not defined","B-cell phenotype mechanism not resolved"]},{"year":2022,"claim":"Identifying non-skeletal roles—limb digit patterning with Sostdc1, joint MMP regulation, and a STAT3 interaction in cancer—broadened SOST function beyond bone Wnt antagonism.","evidence":"Compound knockouts with Shh/Gli epistasis, PTOA transgenic/KO models, and SOST-STAT3 Co-IP with metastasis assays","pmids":["23994639","29377313","36581888"],"confidence":"Medium","gaps":["STAT3 interaction rests on a single-lab Co-IP in cancer context","Mechanistic depth of MMP and developmental roles limited"]},{"year":null,"claim":"How the diverse upstream regulators (mechanical, hormonal, BMP, epigenetic) converge on the MEF2-dependent downstream enhancer to set quantitative SOST output remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No integrated model linking signaling inputs to enhancer occupancy","Structural basis of sclerostin-LRP binding not in corpus","Non-bone functions need independent validation"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,3,18]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[2,3]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,16,35]},{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,18]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[34,35]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,16]}],"complexes":[],"partners":["LRP5","LRP6","STAT3"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BQB4","full_name":"Sclerostin","aliases":[],"length_aa":213,"mass_kda":24.0,"function":"Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation","subcellular_location":"Secreted, extracellular space, extracellular matrix","url":"https://www.uniprot.org/uniprotkb/Q9BQB4/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SOST","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SOST","total_profiled":1310},"omim":[{"mim_id":"614305","title":"SCLEROSTEOSIS 2; SOST2","url":"https://www.omim.org/entry/614305"},{"mim_id":"612354","title":"INFLAMMATORY BOWEL DISEASE 21; IBD21","url":"https://www.omim.org/entry/612354"},{"mim_id":"605740","title":"SCLEROSTIN; SOST","url":"https://www.omim.org/entry/605740"},{"mim_id":"604270","title":"LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 4; LRP4","url":"https://www.omim.org/entry/604270"},{"mim_id":"603507","title":"LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 6; LRP6","url":"https://www.omim.org/entry/603507"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"blood vessel","ntpm":66.6}],"url":"https://www.proteinatlas.org/search/SOST"},"hgnc":{"alias_symbol":["VBCH","DAND6"],"prev_symbol":[]},"alphafold":{"accession":"Q9BQB4","domains":[{"cath_id":"2.10.90.10","chopping":"77-112_130-173","consensus_level":"medium","plddt":88.4302,"start":77,"end":173}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQB4","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQB4-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BQB4-F1-predicted_aligned_error_v6.png","plddt_mean":70.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SOST","jax_strain_url":"https://www.jax.org/strain/search?query=SOST"},"sequence":{"accession":"Q9BQB4","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BQB4.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BQB4/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BQB4"}},"corpus_meta":[{"pmid":"18089564","id":"PMC_18089564","title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18089564","citation_count":1008,"is_preprint":false},{"pmid":"11181578","id":"PMC_11181578","title":"Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST).","date":"2001","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11181578","citation_count":878,"is_preprint":false},{"pmid":"11179006","id":"PMC_11179006","title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein.","date":"2001","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11179006","citation_count":769,"is_preprint":false},{"pmid":"15908424","id":"PMC_15908424","title":"SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15908424","citation_count":603,"is_preprint":false},{"pmid":"11836356","id":"PMC_11836356","title":"Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease.","date":"2002","source":"Journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11836356","citation_count":535,"is_preprint":false},{"pmid":"15946907","id":"PMC_15946907","title":"SOST is a target gene for PTH in bone.","date":"2005","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15946907","citation_count":444,"is_preprint":false},{"pmid":"22075208","id":"PMC_22075208","title":"Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.","date":"2011","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/22075208","citation_count":366,"is_preprint":false},{"pmid":"15869900","id":"PMC_15869900","title":"SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.","date":"2005","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15869900","citation_count":266,"is_preprint":false},{"pmid":"12116252","id":"PMC_12116252","title":"A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population.","date":"2002","source":"American journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12116252","citation_count":241,"is_preprint":false},{"pmid":"19594304","id":"PMC_19594304","title":"Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19594304","citation_count":200,"is_preprint":false},{"pmid":"17696759","id":"PMC_17696759","title":"Control of the SOST bone enhancer by PTH using MEF2 transcription factors.","date":"2007","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/17696759","citation_count":188,"is_preprint":false},{"pmid":"19874086","id":"PMC_19874086","title":"Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.","date":"2010","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/19874086","citation_count":180,"is_preprint":false},{"pmid":"17052975","id":"PMC_17052975","title":"LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17052975","citation_count":177,"is_preprint":false},{"pmid":"19837663","id":"PMC_19837663","title":"The matricellular protein periostin is required for sost inhibition and the anabolic response to mechanical loading and physical activity.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19837663","citation_count":173,"is_preprint":false},{"pmid":"21952235","id":"PMC_21952235","title":"Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21952235","citation_count":156,"is_preprint":false},{"pmid":"23357248","id":"PMC_23357248","title":"Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.","date":"2013","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23357248","citation_count":116,"is_preprint":false},{"pmid":"27163932","id":"PMC_27163932","title":"Protection From Glucocorticoid-Induced Osteoporosis by Anti-Catabolic Signaling in the Absence of Sost/Sclerostin.","date":"2016","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/27163932","citation_count":104,"is_preprint":false},{"pmid":"28529307","id":"PMC_28529307","title":"Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.","date":"2017","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/28529307","citation_count":102,"is_preprint":false},{"pmid":"23362266","id":"PMC_23362266","title":"Estrogen receptor α mediates proliferation of osteoblastic cells stimulated by estrogen and mechanical strain, but their acute down-regulation of the Wnt antagonist Sost is mediated by estrogen receptor β.","date":"2013","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23362266","citation_count":99,"is_preprint":false},{"pmid":"21567076","id":"PMC_21567076","title":"Insulin-dependent diabetes mellitus decreases osteoblastogenesis associated with the inhibition of Wnt signaling through increased expression of Sost and Dkk1 and inhibition of Akt activation.","date":"2011","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21567076","citation_count":98,"is_preprint":false},{"pmid":"20074973","id":"PMC_20074973","title":"Does osteocytic SOST suppression mediate PTH bone anabolism?","date":"2010","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/20074973","citation_count":90,"is_preprint":false},{"pmid":"15514891","id":"PMC_15514891","title":"Polymorphisms in the sclerosteosis/van Buchem disease gene (SOST) region are associated with bone-mineral density in elderly whites.","date":"2004","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15514891","citation_count":87,"is_preprint":false},{"pmid":"17549589","id":"PMC_17549589","title":"Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone.","date":"2007","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/17549589","citation_count":85,"is_preprint":false},{"pmid":"22768243","id":"PMC_22768243","title":"Osteocyte network; a negative regulatory system for bone mass augmented by the induction of Rankl in osteoblasts and Sost in osteocytes at unloading.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22768243","citation_count":85,"is_preprint":false},{"pmid":"31708103","id":"PMC_31708103","title":"Mechanotransduction via the Piezo1-Akt pathway underlies Sost suppression in osteocytes.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31708103","citation_count":77,"is_preprint":false},{"pmid":"25155887","id":"PMC_25155887","title":"Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.","date":"2015","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/25155887","citation_count":76,"is_preprint":false},{"pmid":"21723865","id":"PMC_21723865","title":"Sost down-regulation by mechanical strain in human osteoblastic cells involves PGE2 signaling via EP4.","date":"2011","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/21723865","citation_count":75,"is_preprint":false},{"pmid":"15268896","id":"PMC_15268896","title":"Unique regulation of SOST, the sclerosteosis gene, by BMPs and steroid hormones in human osteoblasts.","date":"2004","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15268896","citation_count":68,"is_preprint":false},{"pmid":"27771382","id":"PMC_27771382","title":"Transcriptional control of Sost in bone.","date":"2016","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/27771382","citation_count":67,"is_preprint":false},{"pmid":"14739291","id":"PMC_14739291","title":"Cbfa1/RUNX2 directs specific expression of the sclerosteosis gene (SOST).","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14739291","citation_count":67,"is_preprint":false},{"pmid":"23901037","id":"PMC_23901037","title":"Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/23901037","citation_count":64,"is_preprint":false},{"pmid":"25757567","id":"PMC_25757567","title":"Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model.","date":"2015","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25757567","citation_count":62,"is_preprint":false},{"pmid":"29863952","id":"PMC_29863952","title":"Role of Osteocyte-PDL Crosstalk in Tooth Movement via SOST/Sclerostin.","date":"2018","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/29863952","citation_count":62,"is_preprint":false},{"pmid":"21221996","id":"PMC_21221996","title":"Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia.","date":"2011","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21221996","citation_count":62,"is_preprint":false},{"pmid":"29080811","id":"PMC_29080811","title":"Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.","date":"2017","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/29080811","citation_count":59,"is_preprint":false},{"pmid":"23776575","id":"PMC_23776575","title":"HIF-1α inhibits Wnt signaling pathway by activating Sost expression in osteoblasts.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23776575","citation_count":55,"is_preprint":false},{"pmid":"19778325","id":"PMC_19778325","title":"Localization of SOST/sclerostin in cementocytes in vivo and in mineralizing periodontal ligament cells in vitro.","date":"2009","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/19778325","citation_count":54,"is_preprint":false},{"pmid":"15869924","id":"PMC_15869924","title":"A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene.","date":"2005","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15869924","citation_count":53,"is_preprint":false},{"pmid":"21787290","id":"PMC_21787290","title":"The role of BMPs in bone anabolism and their potential targets SOST and DKK1.","date":"2012","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21787290","citation_count":51,"is_preprint":false},{"pmid":"31111563","id":"PMC_31111563","title":"microRNA-96 promotes osteoblast differentiation and bone formation in ankylosing spondylitis mice through activating the Wnt signaling pathway by binding to SOST.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31111563","citation_count":50,"is_preprint":false},{"pmid":"21945937","id":"PMC_21945937","title":"Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/21945937","citation_count":50,"is_preprint":false},{"pmid":"21652726","id":"PMC_21652726","title":"Anabolic and catabolic regimens of human parathyroid hormone 1-34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice.","date":"2011","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21652726","citation_count":50,"is_preprint":false},{"pmid":"20583295","id":"PMC_20583295","title":"First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function.","date":"2010","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/20583295","citation_count":49,"is_preprint":false},{"pmid":"29377313","id":"PMC_29377313","title":"SOST/Sclerostin Improves Posttraumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury.","date":"2018","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/29377313","citation_count":48,"is_preprint":false},{"pmid":"25870205","id":"PMC_25870205","title":"Mechanical Force-induced TGFB1 Increases Expression of SOST/POSTN by hPDL Cells.","date":"2015","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/25870205","citation_count":48,"is_preprint":false},{"pmid":"23994639","id":"PMC_23994639","title":"Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner.","date":"2013","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/23994639","citation_count":47,"is_preprint":false},{"pmid":"29750826","id":"PMC_29750826","title":"Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development.","date":"2018","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/29750826","citation_count":43,"is_preprint":false},{"pmid":"27623445","id":"PMC_27623445","title":"Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.","date":"2016","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/27623445","citation_count":43,"is_preprint":false},{"pmid":"23360788","id":"PMC_23360788","title":"High-concentration of BMP2 reduces cell proliferation and increases apoptosis via DKK1 and SOST in human primary periosteal cells.","date":"2013","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/23360788","citation_count":41,"is_preprint":false},{"pmid":"32134561","id":"PMC_32134561","title":"Reduction of SOST gene promotes bone formation through the Wnt/β-catenin signalling pathway and compensates particle-induced osteolysis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32134561","citation_count":39,"is_preprint":false},{"pmid":"27402532","id":"PMC_27402532","title":"Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.","date":"2016","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/27402532","citation_count":39,"is_preprint":false},{"pmid":"19371798","id":"PMC_19371798","title":"The -9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPalpha and FOXA1 binding is associated with osteoporosis.","date":"2009","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/19371798","citation_count":39,"is_preprint":false},{"pmid":"26071314","id":"PMC_26071314","title":"DNA methylation regulates sclerostin (SOST) expression in osteoarthritic chondrocytes by bone morphogenetic protein 2 (BMP-2) induced changes in Smads binding affinity to the CpG region of SOST promoter.","date":"2015","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/26071314","citation_count":38,"is_preprint":false},{"pmid":"17195180","id":"PMC_17195180","title":"SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development.","date":"2007","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/17195180","citation_count":37,"is_preprint":false},{"pmid":"25363869","id":"PMC_25363869","title":"Pigment epithelium derived factor suppresses expression of Sost/Sclerostin by osteocytes: implication for its role in bone matrix mineralization.","date":"2015","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/25363869","citation_count":37,"is_preprint":false},{"pmid":"20948575","id":"PMC_20948575","title":"SOST and DKK: Antagonists of LRP Family Signaling as Targets for Treating Bone Disease.","date":"2010","source":"Journal of osteoporosis","url":"https://pubmed.ncbi.nlm.nih.gov/20948575","citation_count":33,"is_preprint":false},{"pmid":"27600237","id":"PMC_27600237","title":"Cancer-Osteoblast Interaction Reduces Sost Expression in Osteoblasts and Up-Regulates lncRNA MALAT1 in Prostate Cancer.","date":"2015","source":"Microarrays (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/27600237","citation_count":31,"is_preprint":false},{"pmid":"36581888","id":"PMC_36581888","title":"Targeting SOST using a small-molecule compound retards breast cancer bone metastasis.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36581888","citation_count":30,"is_preprint":false},{"pmid":"25847683","id":"PMC_25847683","title":"Lipoprotein receptor-related protein 6 is required for parathyroid hormone-induced Sost suppression.","date":"2015","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25847683","citation_count":30,"is_preprint":false},{"pmid":"12398949","id":"PMC_12398949","title":"Lack of association between the SOST gene and bone mineral density in perimenopausal women: analysis of five polymorphisms.","date":"2002","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/12398949","citation_count":30,"is_preprint":false},{"pmid":"24423318","id":"PMC_24423318","title":"Associations of serum sclerostin and polymorphisms in the SOST gene with bone mineral density and markers of bone metabolism in postmenopausal Chinese women.","date":"2014","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24423318","citation_count":29,"is_preprint":false},{"pmid":"26545120","id":"PMC_26545120","title":"SOST Inhibits Prostate Cancer Invasion.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26545120","citation_count":27,"is_preprint":false},{"pmid":"37121919","id":"PMC_37121919","title":"SOST gene suppression stimulates osteocyte Wnt/β-catenin signaling to prevent bone resorption and attenuates particle-induced osteolysis.","date":"2023","source":"Journal of molecular medicine (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/37121919","citation_count":25,"is_preprint":false},{"pmid":"30820362","id":"PMC_30820362","title":"Characterization of a novel murine Sost ERT2 Cre model targeting osteocytes.","date":"2019","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/30820362","citation_count":25,"is_preprint":false},{"pmid":"39461772","id":"PMC_39461772","title":"The miR-665/SOST Axis Regulates the Phenotypes of Bone Marrow Mesenchymal Stem Cells and Osteoporotic Symptoms in Female Mice.","date":"2024","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/39461772","citation_count":24,"is_preprint":false},{"pmid":"25056116","id":"PMC_25056116","title":"Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.","date":"2014","source":"The Journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/25056116","citation_count":24,"is_preprint":false},{"pmid":"19072561","id":"PMC_19072561","title":"A known SOST gene mutation causes sclerosteosis in a familial and an isolated case from Brazilian origin.","date":"2008","source":"Genetic testing","url":"https://pubmed.ncbi.nlm.nih.gov/19072561","citation_count":24,"is_preprint":false},{"pmid":"19898734","id":"PMC_19898734","title":"Analysis of association of LRP5, LRP6, SOST, DKK1, and CTNNB1 genes with bone mineral density in a Slovenian population.","date":"2009","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/19898734","citation_count":23,"is_preprint":false},{"pmid":"28875158","id":"PMC_28875158","title":"Thirty days of spaceflight does not alter murine calvariae structure despite increased Sost expression.","date":"2017","source":"Bone reports","url":"https://pubmed.ncbi.nlm.nih.gov/28875158","citation_count":23,"is_preprint":false},{"pmid":"23079137","id":"PMC_23079137","title":"Novel SOST gene mutation in a sclerosteosis patient and her parents.","date":"2012","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/23079137","citation_count":21,"is_preprint":false},{"pmid":"27966788","id":"PMC_27966788","title":"Notch Signaling Participates in TGF-β-Induced SOST Expression Under Intermittent Compressive Stress.","date":"2017","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27966788","citation_count":21,"is_preprint":false},{"pmid":"31828128","id":"PMC_31828128","title":"SOST Deficiency Aggravates Osteoarthritis in Mice by Promoting Sclerosis of Subchondral Bone.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31828128","citation_count":21,"is_preprint":false},{"pmid":"28485721","id":"PMC_28485721","title":"SOST silencing promotes proliferation and invasion and reduces apoptosis of retinoblastoma cells by activating Wnt/β-catenin signaling pathway.","date":"2017","source":"Gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28485721","citation_count":21,"is_preprint":false},{"pmid":"30257098","id":"PMC_30257098","title":"Methylation of bone SOST impairs SP7, RUNX2, and ERα transactivation in patients with postmenopausal osteoporosis.","date":"2018","source":"Biochemistry and cell biology = Biochimie et biologie cellulaire","url":"https://pubmed.ncbi.nlm.nih.gov/30257098","citation_count":19,"is_preprint":false},{"pmid":"27601226","id":"PMC_27601226","title":"Sost, independent of the non-coding enhancer ECR5, is required for bone mechanoadaptation.","date":"2016","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/27601226","citation_count":19,"is_preprint":false},{"pmid":"29307778","id":"PMC_29307778","title":"Computational and functional characterization of four SNPs in the SOST locus associated with osteoporosis.","date":"2018","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/29307778","citation_count":18,"is_preprint":false},{"pmid":"26095393","id":"PMC_26095393","title":"Inhibition of GSK3β Stimulates BMP Signaling and Decreases SOST Expression Which Results in Enhanced Osteoblast Differentiation.","date":"2015","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26095393","citation_count":18,"is_preprint":false},{"pmid":"28246931","id":"PMC_28246931","title":"Effects of SOST Gene Silencing on Proliferation, Apoptosis, Invasion, and Migration of Human Osteosarcoma Cells Through the Wnt/β-Catenin Signaling Pathway.","date":"2017","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/28246931","citation_count":18,"is_preprint":false},{"pmid":"24322886","id":"PMC_24322886","title":"Nitric oxide is involved in the down-regulation of SOST expression induced by mechanical loading.","date":"2013","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/24322886","citation_count":18,"is_preprint":false},{"pmid":"30041240","id":"PMC_30041240","title":"SOST Gene Inhibits Osteogenesis from Adipose-Derived Mesenchymal Stem Cells by Inducing Th17 Cell Differentiation.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30041240","citation_count":16,"is_preprint":false},{"pmid":"22364398","id":"PMC_22364398","title":"Combinatorial use of bone morphogenetic protein 6, noggin and SOST significantly predicts cancer progression.","date":"2012","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/22364398","citation_count":16,"is_preprint":false},{"pmid":"27519970","id":"PMC_27519970","title":"Variations of SOST mRNA expression in human bone are associated with DNA polymorphism and DNA methylation in the SOST gene.","date":"2016","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/27519970","citation_count":16,"is_preprint":false},{"pmid":"22076526","id":"PMC_22076526","title":"Association study of polymorphisms in the SOST gene region and parameters of bone strength and body composition in both young and elderly men: data from the Odense Androgen Study.","date":"2011","source":"Calcified tissue international","url":"https://pubmed.ncbi.nlm.nih.gov/22076526","citation_count":16,"is_preprint":false},{"pmid":"30894984","id":"PMC_30894984","title":"Expression of SOST/sclerostin in compressed periodontal ligament cells.","date":"2016","source":"Journal of dental sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30894984","citation_count":15,"is_preprint":false},{"pmid":"27524798","id":"PMC_27524798","title":"Distorted Patterns of Dentinogenesis and Eruption in Msx2 Null Mutants: Involvement of Sost/Sclerostin.","date":"2016","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/27524798","citation_count":15,"is_preprint":false},{"pmid":"29226516","id":"PMC_29226516","title":"SOST, an LNGFR target, inhibits the osteogenic differentiation of rat ectomesenchymal stem cells.","date":"2017","source":"Cell proliferation","url":"https://pubmed.ncbi.nlm.nih.gov/29226516","citation_count":14,"is_preprint":false},{"pmid":"26690786","id":"PMC_26690786","title":"Early response of the human SOST gene to stimulation by 1α,25-dihydroxyvitamin D3.","date":"2015","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26690786","citation_count":14,"is_preprint":false},{"pmid":"39342093","id":"PMC_39342093","title":"SOST/Sclerostin impairs the osteogenesis and angiogesis in glucocorticoid-associated osteonecrosis of femoral head.","date":"2024","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/39342093","citation_count":13,"is_preprint":false},{"pmid":"35278242","id":"PMC_35278242","title":"Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.","date":"2022","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/35278242","citation_count":13,"is_preprint":false},{"pmid":"37612291","id":"PMC_37612291","title":"Inhibiting WNT secretion reduces high bone mass caused by Sost loss-of-function or gain-of-function mutations in Lrp5.","date":"2023","source":"Bone research","url":"https://pubmed.ncbi.nlm.nih.gov/37612291","citation_count":13,"is_preprint":false},{"pmid":"30026596","id":"PMC_30026596","title":"Common and rare variants of WNT16, DKK1 and SOST and their relationship with bone mineral density.","date":"2018","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30026596","citation_count":13,"is_preprint":false},{"pmid":"30729116","id":"PMC_30729116","title":"Expression of Sclerostin in Osteoporotic Fracture Patients Is Associated with DNA Methylation in the CpG Island of the SOST Gene.","date":"2019","source":"International journal of genomics","url":"https://pubmed.ncbi.nlm.nih.gov/30729116","citation_count":13,"is_preprint":false},{"pmid":"32793634","id":"PMC_32793634","title":"lncRNA MEG3 Suppresses the Progression of Ankylosis Spondylitis by Regulating the Let-7i/SOST Axis.","date":"2020","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/32793634","citation_count":13,"is_preprint":false},{"pmid":"25430630","id":"PMC_25430630","title":"Analysis of association of MEF2C, SOST and JAG1 genes with bone mineral density in Mexican-Mestizo postmenopausal women.","date":"2014","source":"BMC musculoskeletal disorders","url":"https://pubmed.ncbi.nlm.nih.gov/25430630","citation_count":13,"is_preprint":false},{"pmid":"31774873","id":"PMC_31774873","title":"Polymorphisms of FDPS, LRP5, SOST and VKORC1 genes and their relation with osteoporosis in postmenopausal Romanian women.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31774873","citation_count":12,"is_preprint":false},{"pmid":"27723935","id":"PMC_27723935","title":"N-cadherin restrains PTH repressive effects on sclerostin/SOST by regulating LRP6-PTH1R interaction.","date":"2016","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27723935","citation_count":12,"is_preprint":false},{"pmid":"26250343","id":"PMC_26250343","title":"SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.","date":"2015","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/26250343","citation_count":12,"is_preprint":false},{"pmid":"29349060","id":"PMC_29349060","title":"Sost Deficiency does not Alter Bone's Lacunar or Vascular Porosity in Mice.","date":"2017","source":"Frontiers in materials","url":"https://pubmed.ncbi.nlm.nih.gov/29349060","citation_count":11,"is_preprint":false},{"pmid":"33339872","id":"PMC_33339872","title":"Cortical bone adaptation to a moderate level of mechanical loading in male Sost deficient mice.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33339872","citation_count":11,"is_preprint":false},{"pmid":"28235973","id":"PMC_28235973","title":"Endothelin signaling regulates mineralization and posttranscriptionally regulates SOST in TMOb cells via miR 126-3p.","date":"2017","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/28235973","citation_count":11,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":55012,"output_tokens":9379,"usd":0.152861,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19421,"output_tokens":4999,"usd":0.11104,"stage2_stop_reason":"end_turn"},"total_usd":0.263901,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Loss-of-function mutations in the SOST gene (nonsense and splice site mutations) cause sclerosteosis, establishing that the SOST protein product (sclerostin) is a secreted negative regulator of bone formation. The protein contains a signal peptide and a cysteine-knot motif, placing it in the DAN family of cystine knot-containing factors.\",\n      \"method\": \"Positional cloning, mutation analysis in sclerosteosis patients, protein domain analysis\",\n      \"journal\": \"Human molecular genetics / American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — independently replicated by two groups (PMID:11181578 and PMID:11179006) using positional cloning and mutation identification in affected families\",\n      \"pmids\": [\"11181578\", \"11179006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Van Buchem disease is caused by a 52-kb deletion located ~35 kb downstream of the SOST gene (not within its coding region), establishing that this non-coding region contains a cis-regulatory element essential for SOST transcription in bone.\",\n      \"method\": \"Linkage analysis, deletion mapping, haplotype analysis in van Buchem families\",\n      \"journal\": \"Journal of medical genetics / American journal of medical genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — independently identified by two groups (PMID:11836356 and PMID:12116252) using genetic mapping and deletion characterization\",\n      \"pmids\": [\"11836356\", \"12116252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"SOST/sclerostin antagonizes Wnt signaling by directly binding to the extracellular domain of the Wnt co-receptors LRP5 and LRP6, disrupting Wnt-induced Frizzled-LRP complex formation.\",\n      \"method\": \"Binding assays (LRP5/LRP6 extracellular domain binding), Xenopus embryo Wnt antagonism assay, mammalian cell Wnt reporter assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding demonstrated in multiple systems (Xenopus and mammalian cells) with functional Wnt inhibition readout; replicated by subsequent LRP5 HBM mutation study (PMID:17052975)\",\n      \"pmids\": [\"15908424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"LRP5 high bone mass (HBM) mutations cluster in the extracellular domain and reduce LRP5 binding to SOST, rendering LRP5 more refractory to inhibition by sclerostin, mechanistically linking SOST-LRP5 antagonism to bone mass regulation.\",\n      \"method\": \"Binding assays comparing SOST interaction with wild-type vs. HBM mutant LRP5 proteins, functional Wnt inhibition assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding measurements with multiple mutants, consistent with prior SOST-LRP5 binding data\",\n      \"pmids\": [\"17052975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PTH directly suppresses SOST transcription in vivo and in vitro via the cAMP/PKA pathway; the effect is not blocked by cycloheximide (indicating direct transcriptional regulation) and PTH does not alter SOST mRNA stability, pointing to transcriptional rather than post-transcriptional control.\",\n      \"method\": \"In vivo PTH administration (calvarial, systemic, intermittent) + qPCR; in vitro UMR-106 cell treatment with PTH, PKA/PKC pathway inhibitors/activators, cycloheximide, and PTH antagonist\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo and in vitro models, pharmacological dissection of signaling pathway, replicated across multiple labs in subsequent papers\",\n      \"pmids\": [\"15946907\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MEF2 transcription factors (MEF2A, MEF2C, MEF2D) bind a MEF2 response element in the SOST bone enhancer (within the 52-kb van Buchem deletion) to activate SOST transcription in osteocytes; PTH suppresses SOST by inhibiting this MEF2-dependent enhancer activity rather than the SOST promoter.\",\n      \"method\": \"Luciferase reporter assays, footprint/mutation analysis, gel retardation (EMSA), antibody supershift, siRNA knockdown of MEF2 isoforms, ISH/IHC co-localization in bone\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — multiple orthogonal methods (EMSA, reporter, siRNA) in a single focused study with rigorous controls\",\n      \"pmids\": [\"17696759\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Mechanical loading (ulnar loading) dramatically reduces Sost mRNA and sclerostin protein in osteocytes in a strain-magnitude-dependent manner, while hindlimb unloading increases Sost expression, establishing osteocyte-expressed sclerostin as a mechanically regulated bone formation inhibitor.\",\n      \"method\": \"In vivo ulnar loading and hindlimb unloading models; ISH (Sost mRNA) and IHC (sclerostin protein) in mouse tibia/ulna\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two complementary mechanical models with both mRNA and protein readouts; widely replicated by subsequent studies\",\n      \"pmids\": [\"18089564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sost downregulation in osteocytes is an obligatory step in the mechanotransduction cascade: transgenic mice engineered to maintain high SOST expression during loading showed 70-85% reduction in load-induced bone formation and absence of Wnt target gene induction, demonstrating that sclerostin suppression is required to unleash local Wnt signaling for osteogenesis.\",\n      \"method\": \"In vivo ulnar loading in SOST-transgenic mice (DMP1-driven human SOST transgene) vs. wild-type; bone formation histomorphometry; Wnt target gene qPCR\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic gain-of-function model with direct epistasis test, multiple orthogonal readouts (histomorphometry + gene expression)\",\n      \"pmids\": [\"22075208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RUNX2/Cbfa1 binds the proximal SOST promoter and contributes to differential SOST expression in osteosarcoma cells, and an E-box binding motif in the 1.8-kb proximal SOST promoter is also functional in SAOS-2 cells.\",\n      \"method\": \"Gel shift (EMSA), transient transfection luciferase assays in osteosarcoma cell lines\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — EMSA and reporter assays in a single study, single lab\",\n      \"pmids\": [\"14739291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"BMP-2, BMP-4, and BMP-6 induce SOST expression in human osteoblasts in a time- and dose-dependent manner; this effect is enhanced by retinoic acid and 1,25-dihydroxyvitamin D3, but blocked by dexamethasone. This regulation differs from other BMP antagonists (noggin, gremlin), indicating unique upstream control of SOST.\",\n      \"method\": \"RT-PCR/Northern analysis in human osteoblast cultures treated with BMPs, steroids, and growth factors\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — mRNA expression assays in multiple treatment conditions, replicated directionally in subsequent studies (PMID:19874086, PMID:21945937)\",\n      \"pmids\": [\"15268896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"BMP signaling through BMPRIA in osteoblasts positively regulates Sost and Dkk1 expression: conditional knockout of Bmpr1a in osteoblasts reduces Sost and Dkk1 levels and increases Wnt/β-catenin signaling; BMP2 upregulates and Noggin downregulates both inhibitors; BMP2-induced Dkk1 (but not Sost) is blocked by p38 MAPK inhibition, indicating differential downstream signaling.\",\n      \"method\": \"Conditional knockout mice (Bmpr1a cKO), Wnt reporter assays (TOPGAL, TOPFLASH), BMP2/Noggin/dorsomorphin treatment, SB202190 inhibitor; qPCR\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO combined with pharmacological tools and multiple Wnt reporter readouts, single lab but multiple orthogonal approaches\",\n      \"pmids\": [\"19874086\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Loss of ACVR1 (BMP receptor for BMP7) specifically in osteoblasts increases bone mass and suppresses expression of both Sost and Dkk1, activating canonical Wnt signaling; BMP7 dose-dependently upregulates Sost and Dkk1 in vitro, defining a BMP7-ACVR1-SOST/DKK1 axis.\",\n      \"method\": \"Inducible osteoblast-specific Acvr1 conditional KO mice, qPCR, in vitro BMP7 treatment of osteoblasts\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic KO model with gene expression validation, single lab, limited mechanistic depth\",\n      \"pmids\": [\"21945937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Sirt1 directly represses Sost gene expression by deacetylating histone 3 at lysine 9 at the Sost promoter, as demonstrated by chromatin immunoprecipitation; Sirt1 haploinsufficiency increases sclerostin levels and reduces bone formation.\",\n      \"method\": \"ChIP analysis in Sirt1+/- mice; siRNA knockdown of Sost; sclerostin-neutralizing antibody rescue experiments; osteocalcin/bone sialoprotein gene expression and mineralization assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP showing direct histone deacetylation at Sost promoter, functional rescue experiments; single lab\",\n      \"pmids\": [\"21952235\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Strain-induced Sost downregulation in human osteoblastic cells (Saos2) is mediated by COX-2-dependent prostaglandin E2 (PGE2) acting through the EP4 receptor and requires ERK signaling; strain-induced osteocalcin upregulation uses the EP2 receptor and PKC, demonstrating early pathway divergence.\",\n      \"method\": \"Dynamic strain of Saos2 cells; COX-2 inhibitors; EP receptor agonists/antagonists; MEK/ERK inhibitors; qRT-PCR\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological dissection in a cell line with multiple pathway inhibitors, single lab\",\n      \"pmids\": [\"21723865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Estrogen receptor β (ERβ), not ERα, mediates the acute down-regulation of Sost expression by mechanical strain and estradiol in osteoblastic cells; ERβ agonists recapitulate Sost suppression, ERβ antagonist or ERβ deletion prevents it, and the effect requires MEK/ERK signaling.\",\n      \"method\": \"ERα/ERβ selective agonists/antagonists in mouse long bone osteoblasts and Saos-2 cells; in vivo ERα-null mouse; ERβ-null osteoblasts; MEK/ERK inhibitors; qPCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal pharmacological and genetic approaches in vitro and in vivo, single lab\",\n      \"pmids\": [\"23362266\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"HIF-1α transcriptionally activates Sost expression in osteoblasts under hypoxia by directly binding a hypoxia response element in the Sost promoter (within the −260 bp minimal region); HIF-1α siRNA reduces Sost expression; DFO (HIF-1α activator) further increases Sost.\",\n      \"method\": \"qRT-PCR; siRNA knockdown of HIF-1α; deletion mutant Sost promoter-luciferase reporters; gel shift (EMSA); DFO treatment of osteoblasts\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 / Weak — promoter deletion analysis, EMSA, and siRNA in a single study; single lab\",\n      \"pmids\": [\"23776575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Signal peptide mutations (Val21Met, Val21Leu) in the SOST gene cause autosomal dominant craniodiaphyseal dysplasia by dramatically reducing SOST secretion, acting through a dominant negative mechanism distinct from the recessive loss-of-function mutations causing sclerosteosis/van Buchem disease.\",\n      \"method\": \"Transfection of mutant SOST constructs into 293E cells; secretion assay\",\n      \"journal\": \"Human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — direct secretion assay with mutant constructs, single study with clear functional readout\",\n      \"pmids\": [\"21221996\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The missense mutation p.Cys167Arg in the SOST cystine-knot motif causes retention of mutant sclerostin in the ER (impaired folding/secretion) and significantly reduces LRP5 binding and Wnt signaling inhibition, establishing that the cystine-knot integrity is required for sclerostin's secretion and function.\",\n      \"method\": \"Functional assays: LRP5 binding assay, Wnt signaling reporter assay, ER retention/secretion assay in transfected cells\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — multiple functional approaches (binding, Wnt reporter, secretion) in a single study; single lab\",\n      \"pmids\": [\"20583295\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Sost deficiency-induced bone anabolism partially requires LRP5, but fully depends on Wnt1 class-induced LRP6 activity: selective blockade of Wnt1-class LRP6 signaling completely reversed bone overgrowth in Sost-/- and Sost-/-;Lrp5-/- mice to wild-type levels.\",\n      \"method\": \"Sost-/-;Lrp5-/- double knockout mice; treatment with class-selective anti-LRP6 antibodies; microCT and histomorphometry\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (double KO) combined with pharmacological LRP6 antibody intervention, multiple skeletal parameters measured\",\n      \"pmids\": [\"23901037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DNA methylation of the SOST promoter CpG region regulates SOST expression in osteoarthritic chondrocytes; BMP-2 increases SOST expression via Smad1/5/8 binding to the hypomethylated CpG region of the SOST promoter, as shown by ChIP; 5-AzadC (demethylation) increases SOST expression.\",\n      \"method\": \"Methylation-specific PCR, bisulfite sequencing, 5-AzadC treatment, ChIP for Smad1/5/8 binding, qRT-PCR and Western blot in OA chondrocytes\",\n      \"journal\": \"Arthritis research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — ChIP plus epigenetic manipulation, single lab, limited mechanistic depth\",\n      \"pmids\": [\"26071314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"LRP6 is required for PTH-induced suppression of Sost in osteocytes: osteoblast-specific Lrp6 KO mice show elevated Sost/sclerostin levels and blunted PTH-induced Sost suppression; PTH-induced downregulation of MEF2C/D and HDAC changes in osteocytes were abrogated in LRP6-KO mice.\",\n      \"method\": \"Osteoblast-specific Lrp6-KO mice; intermittent PTH treatment; qPCR for Sost; IHC for sclerostin+ osteocytes; MEF2 and HDAC protein analysis\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — genetic KO model with PTH challenge, multiple molecular readouts; single lab\",\n      \"pmids\": [\"25847683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"N-cadherin restrains PTH-mediated suppression of sclerostin/SOST by reducing LRP6-PTH1R interaction and endocytosis; overexpression of N-cadherin blunts PTH-induced downregulation of MEF2A/C/D and SOST; osteocyte-specific N-cadherin deletion (Cdh2ΔDmp1) accentuates iPTH-induced SOST suppression and enhances PTH bone anabolic effects.\",\n      \"method\": \"N-cadherin overexpression in vitro; osteocyte-specific Cdh2 KO (Dmp1-Cre) mice; iPTH treatment; LRP6-PTHR1 co-IP/endocytosis; qPCR; immunoblot\",\n      \"journal\": \"Annals of the New York Academy of Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro overexpression and in vivo genetic model with multiple mechanistic readouts; single lab\",\n      \"pmids\": [\"27723935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Mechanical stretch-induced suppression of Sost expression in osteocytes (IDG-SW3 cells) is mediated by the mechanosensitive ion channel Piezo1 and requires downstream Akt activation; Piezo1 agonist (Yoda1) decreases Sost expression, and this is abrogated by Piezo1 inhibitor GsMTx4, Piezo1 deficiency, or Akt inhibition.\",\n      \"method\": \"IDG-SW3 osteocyte cell line; Yoda1 treatment; mechanical stretch; GsMTx4 (Piezo1 inhibitor); Piezo1 siRNA/knockout; Akt inhibitor; qPCR for Sost; intracellular calcium imaging\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic loss-of-function of Piezo1, plus kinase inhibition, multiple orthogonal approaches in a single study\",\n      \"pmids\": [\"31708103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The matricellular protein periostin (Postn) is required for mechanical stimulation-induced inhibition of Sost in bone; Postn-/- mice have elevated baseline Sost expression that is unresponsive to exercise/loading, and sclerostin-blocking antibody rescues the impaired bone biomechanical response in these mice.\",\n      \"method\": \"Postn-/- mice; exercise and axial tibial compression models; anti-sclerostin antibody rescue; bone microarchitecture and biomechanics; gene expression (Sost, periostin)\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model, mechanical challenge, and antibody rescue; multiple readouts; single lab\",\n      \"pmids\": [\"19837663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Nitric oxide (NO) is involved in pulsating fluid flow (PFF)-induced downregulation of SOST expression in human bone cells; NOS inhibitor 1400W prevents the PFF effect on SOST; NO donor SNAP decreases SOST mRNA; conditioned medium from PFF-stimulated cells decreases SOST promoter transcriptional activity, indicating secreted factors also contribute.\",\n      \"method\": \"Pulsating fluid flow on AzadC-treated human bone cells; NOS inhibitor (1400W); NO donor (SNAP); SOST promoter-reporter assay; conditioned medium transfer\",\n      \"journal\": \"Calcified tissue international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological NOS inhibition and NO donor, promoter reporter, conditioned medium assay; single lab\",\n      \"pmids\": [\"24322886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"PIGMENT EPITHELIUM DERIVED FACTOR (PEDF) suppresses Sost/sclerostin expression by 70% in mineralizing osteoblast cultures and by 50% in primary osteocytes, leading to increased total β-catenin (Wnt signaling activation) and enhanced mineralization.\",\n      \"method\": \"Exogenous PEDF treatment of mineralizing human osteoblast cultures and primary osteocytes; qRT-PCR; Western blot; immunoprecipitation; β-catenin assay\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single-method expression assays and western blot; mechanism upstream of PEDF-SOST link not fully defined; single lab\",\n      \"pmids\": [\"25363869\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Sclerostin (SOST) inhibits MMP2/3 expression and activity after joint injury; SOST transgenic mice develop less severe PTOA and osteophytes, with ~2-fold less MMP activation; intra-articular recombinant Sost protein post-injury decreases MMP activity; Sost induction in response to joint injury is TNFα and NF-κB dependent.\",\n      \"method\": \"SOST transgenic and Sost-/- mice; noninvasive tibial compression overload PTOA model; MMP activity quantification; MMP2/3 protein measurement; recombinant Sost intra-articular injection; TNFα and NF-κB pathway analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic gain-of-function and KO loss-of-function plus recombinant protein rescue; multiple orthogonal readouts; single lab\",\n      \"pmids\": [\"29377313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SOST is expressed in the medial vessel wall smooth muscle cells of the great arteries (ascending aorta, aortic arch, brachiocephalic, common carotids, pulmonary trunk) from embryonic day 15.5 to neonatal period, but its expression does not correspond with inhibition of Smad-dependent BMP or β-catenin-dependent Wnt activity in these vessels.\",\n      \"method\": \"In situ hybridization and IHC for SOST/sclerostin; BMP signaling (pSmad) and Wnt (β-catenin) reporter/IHC in mouse embryo cardiovascular tissue sections\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — localization by ISH/IHC with negative functional correlation; no direct functional experiment on SOST in vasculature\",\n      \"pmids\": [\"17195180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The human SOST gene is directly and positively regulated by 1α,25-dihydroxyvitamin D3 (1,25D) in osteocyte-like SaOS2 cells, mediated at least in part by a DR3-type vitamin D response element; SOST mRNA and sclerostin protein increase within 3 hours of 1,25D treatment and decrease within 3 hours of PTH treatment.\",\n      \"method\": \"1,25D and PTH treatment of differentiated SaOS2 osteocyte-like cells; qRT-PCR and protein measurement at early time points; CYP24A1 induction assay\",\n      \"journal\": \"The Journal of steroid biochemistry and molecular biology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — mRNA and protein expression assays, functional VDRE implied but not fully characterized; single lab, cell line only\",\n      \"pmids\": [\"26690786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Compressive force upregulates SOST (and POSTN) expression in human PDL fibroblasts via TGF-β1: cycloheximide, TGF-β inhibitor (SB431542), or TGF-β1 neutralizing antibody attenuate force-induced SOST and POSTN expression; TGF-β1 accumulates intracellularly/in matrix (not in medium) in response to force.\",\n      \"method\": \"Computer-controlled compressive force loading apparatus on hPDL cells; qRT-PCR; Western blot; cycloheximide; TGF-β receptor inhibitor; neutralizing antibody; ELISA for TGF-β1\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological and antibody blockade of TGF-β pathway; single lab; limited depth\",\n      \"pmids\": [\"25870205\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Notch signaling participates in TGF-β-induced SOST expression in human PDL cells under compressive stress: compressive force induces NOTCH2, NOTCH3, HES1, HEY1; γ-secretase inhibitor (DAPT) reduces stress-induced SOST; TGF-β receptor inhibitor reduces Notch activation; recombinant TGF-β1 enhances SOST and Notch gene expression, and DAPT attenuates TGF-β1-induced SOST.\",\n      \"method\": \"Intermittent compressive stress apparatus on hPDL cells; TGF-β receptor inhibitor (SB431542); γ-secretase inhibitor (DAPT); recombinant TGF-β1; qPCR; Western blot\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — pharmacological pathway inhibition showing sequential TGF-β/Notch/SOST axis; single lab\",\n      \"pmids\": [\"27966788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Osteocyte-derived sclerostin impairs osteogenesis and angiogenesis via inhibiting the Wnt pathway; co-culture of osteocytes with MC3T3-E1 or endothelial cells in the presence of dexamethasone worsened inhibition, and SOST-silencing of osteocytes rescued these effects; in vivo SOST KO ameliorated glucocorticoid-associated osteonecrosis of femoral head.\",\n      \"method\": \"Co-culture of Ocy454 osteocytes (± SOST silencing) with MC3T3-E1 and endothelial cells + dexamethasone; SOST KO rat GA-ONFH model; histology, IHC, bone metabolic markers\",\n      \"journal\": \"Molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — co-culture mechanistic model plus in vivo KO; single lab; mechanism (Wnt pathway inhibition) inferred from pathway markers\",\n      \"pmids\": [\"39342093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Osteocyte Dmp1-Cre-specific deletion of Bmpr1a reduces Sost mRNA in bone by >95% and serum SOST protein by ~85%, activates Wnt/β-catenin signaling, and also dramatically decreases RANKL while increasing OPG, leading to osteosclerosis—establishing that BMP signaling through BMPR1A in osteocytes positively regulates Sost expression.\",\n      \"method\": \"Dmp1-Cre conditional Bmpr1a KO mice; microCT; histomorphometry; qPCR; ELISA for serum SOST and RANKL; β-catenin/Tcf target gene expression; mechanical testing\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — osteocyte-specific genetic KO with comprehensive molecular, cellular and structural phenotyping; multiple orthogonal readouts\",\n      \"pmids\": [\"27402532\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SOST interacts with STAT3 to enhance TGF-β/KRAS signaling in breast cancer cells, increasing tumor growth and bone metastasis; SOST silencing reduces bone metastatic capacity of SCP2 cells; small molecule S6 inhibiting SOST-STAT3 interaction suppresses breast cancer growth and bone metastasis in vivo.\",\n      \"method\": \"Co-IP (SOST-STAT3 interaction); SOST silencing/overexpression in SCP2 cells; in vitro and in vivo bone metastasis assays; small molecule screen; breast cancer organoid treatment\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP for SOST-STAT3 binding plus in vivo functional studies; single lab; novel context (cancer) requires further validation\",\n      \"pmids\": [\"36581888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Sost and its paralog Sostdc1 coordinately regulate digit number: in the developing limb, Sost is restricted to distal ectoderm and Sostdc1 to proximal ectoderm/mesenchyme; Sost-/-;Sostdc1-/- double KO mice show elevated Wnt signaling leading to misregulation of SHH signaling, ectopic Sox9 activation, and preaxial polydactyly in a Gli1/Gli3-dependent manner; syndactyly in Sost-/- is driven by misregulation of Fgf8 in the AER.\",\n      \"method\": \"Sost-/-, Sostdc1-/-, and double KO mice; limb phenotype analysis; Shh/Gli signaling analysis; ISH; epistasis with Gli1/Gli3 mutants\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic models with pathway epistasis analysis; single lab\",\n      \"pmids\": [\"23994639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Multiple osteoblast lineage cell types contribute paracrine sclerostin to the bone microenvironment: conditional deletion of Sost in Prx1 (osteoprogenitor), Col1 (midstage osteoblast), Dmp1 (mature osteocyte), and ColX (hypertrophic chondrocyte) lineages all increased trabecular bone mass; only Prx1-Cre deletion fully recapitulated the full HBM phenotype and the B-cell defect of global Sost KO. Sclerostin from axial skeleton does not influence appendicular bone in a circulating endocrine manner.\",\n      \"method\": \"Cell type-specific conditional Sost KO mice (4 Cre lines); microCT; DXA; cortical bone histomorphometry; B-cell FACS analysis\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — four independent conditional KO models enabling dissection of cell-type contributions and paracrine vs. endocrine action; single lab with comprehensive phenotyping\",\n      \"pmids\": [\"29750826\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Sclerostin (SOST) is a secreted cystine-knot glycoprotein produced predominantly by osteocytes that inhibits bone formation by directly binding to the extracellular domain of the Wnt co-receptors LRP5 and LRP6, disrupting Frizzled-LRP complex formation and suppressing canonical Wnt/β-catenin signaling; its transcription in osteocytes is driven by MEF2 transcription factors acting on a bone-specific enhancer ~35 kb downstream of the gene, is positively regulated by BMP signaling through BMPRIA/ACVR1, and is suppressed by mechanical loading (via Piezo1-Akt and PGE2/EP4-ERK pathways), PTH (via cAMP/PKA-MEF2 axis requiring LRP6), Sirt1 (via histone H3K9 deacetylation), and estrogen receptor β; loss-of-function mutations in SOST cause sclerosteosis/van Buchem disease due to unopposed Wnt signaling and consequent bone overgrowth.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Sclerostin (SOST) is a secreted cystine-knot glycoprotein produced predominantly by osteocytes and osteoblast-lineage cells that acts as a paracrine negative regulator of bone formation [#0, #35]. It functions by directly binding the extracellular domains of the Wnt co-receptors LRP5 and LRP6, disrupting Wnt-induced Frizzled-LRP complex formation and thereby suppressing canonical Wnt/\\u03b2-catenin signaling [#2]; high-bone-mass LRP5 mutations that weaken this interaction render the receptor refractory to sclerostin inhibition [#3], and Sost-deficiency-driven bone anabolism depends partially on LRP5 but fully on Wnt1-class LRP6 activity [#18]. Integrity of the cystine-knot motif and an intact signal peptide are required for sclerostin folding, secretion, and LRP5 binding [#16, #17]. SOST transcription in osteocytes is controlled through a bone-specific enhancer ~35 kb downstream of the gene, where MEF2 transcription factors (MEF2A/C/D) drive expression [#5]; this enhancer region is the element deleted in van Buchem disease [#1]. SOST is positively regulated by BMP signaling acting through osteoblast/osteocyte BMPRIA and ACVR1 receptors [#10, #11, #32] and is suppressed by mechanical loading and by PTH, the latter via a cAMP/PKA pathway that targets the MEF2-dependent enhancer rather than the promoter [#4, #5, #6]. Mechanically induced suppression of SOST is an obligatory step in load-induced osteogenesis: forced maintenance of SOST during loading abolishes the Wnt-driven bone formation response [#7], and is transduced via the mechanosensitive channel Piezo1\\u2013Akt axis, COX-2/PGE2\\u2013EP4\\u2013ERK signaling, estrogen receptor \\u03b2, periostin, and nitric oxide [#22, #13, #14, #23, #24]. Recessive loss-of-function SOST mutations cause sclerosteosis and van Buchem disease through unopposed Wnt signaling and bone overgrowth, while dominant-negative signal-peptide mutations that block secretion cause craniodiaphyseal dysplasia [#0, #1, #16]. Beyond bone, SOST has been implicated in limb digit patterning together with its paralog Sostdc1 [#34] and in breast cancer bone metastasis via a STAT3 interaction [#33].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Establishing that SOST encodes a secreted bone-formation inhibitor answered what gene underlies sclerosteosis and placed sclerostin in the cystine-knot factor family.\",\n      \"evidence\": \"Positional cloning and mutation analysis in sclerosteosis families with protein domain analysis\",\n      \"pmids\": [\"11181578\", \"11179006\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of secreted sclerostin not yet identified\", \"Cell of origin within bone not yet defined\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapping van Buchem disease to a downstream non-coding deletion revealed that a distant cis-regulatory element, not the coding sequence, governs SOST expression in bone.\",\n      \"evidence\": \"Linkage analysis and deletion mapping in van Buchem families\",\n      \"pmids\": [\"11836356\", \"12116252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the transcription factors acting on the enhancer not yet known\", \"Tissue specificity of the element not yet dissected\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrating direct binding of sclerostin to LRP5/LRP6 defined the molecular mechanism by which SOST inhibits bone formation\\u2014antagonism of canonical Wnt signaling.\",\n      \"evidence\": \"LRP extracellular-domain binding assays plus Xenopus and mammalian Wnt reporter assays\",\n      \"pmids\": [\"15908424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of LRP5 vs LRP6 in vivo not resolved\", \"Structural basis of binding not determined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showing that LRP5 high-bone-mass mutations reduce sclerostin binding mechanistically linked the SOST-LRP5 interaction directly to bone mass set-point.\",\n      \"evidence\": \"Binding and Wnt-inhibition assays comparing wild-type vs HBM mutant LRP5\",\n      \"pmids\": [\"17052975\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address LRP6 contribution\", \"In vivo consequences of altered binding inferred not measured\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identifying that PTH suppresses SOST transcription via cAMP/PKA, independent of protein synthesis, established hormonal control of sclerostin as direct and transcriptional.\",\n      \"evidence\": \"In vivo PTH administration plus UMR-106 cell pharmacology with cycloheximide and PKA modulators\",\n      \"pmids\": [\"15946907\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcription factor target downstream of PKA not identified in this study\", \"Specific cis-element not localized here\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Localizing MEF2 binding to the downstream bone enhancer connected the van Buchem regulatory region to its transcription factors and revealed PTH acts on the enhancer rather than the promoter.\",\n      \"evidence\": \"EMSA, reporter assays, siRNA knockdown of MEF2 isoforms, and bone co-localization\",\n      \"pmids\": [\"17696759\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals coupling PTH/PKA to MEF2 inactivation not fully defined\", \"Chromatin context of enhancer not characterized\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing that mechanical loading reduces and unloading increases osteocyte sclerostin established SOST as a strain-responsive regulator of bone formation.\",\n      \"evidence\": \"In vivo ulnar loading and hindlimb unloading with Sost mRNA and protein readouts\",\n      \"pmids\": [\"18089564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanotransduction pathway upstream of Sost not yet identified\", \"Whether suppression is required for osteogenesis not yet tested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Engineering persistent SOST during loading proved that sclerostin downregulation is an obligatory step for load-induced Wnt activation and bone formation.\",\n      \"evidence\": \"Ulnar loading of DMP1-driven SOST-transgenic mice with histomorphometry and Wnt target qPCR\",\n      \"pmids\": [\"22075208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sensors and intermediate signaling not addressed in this model\", \"Residual bone formation source not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Genetic and pharmacological dissection of BMP receptors established that BMP signaling through BMPRIA and ACVR1 positively regulates Sost expression, with osteocyte BMPR1A deletion nearly abolishing Sost.\",\n      \"evidence\": \"Conditional Bmpr1a and Acvr1 knockouts, BMP/Noggin treatment, Wnt reporters, and serum SOST ELISA\",\n      \"pmids\": [\"19874086\", \"21945937\", \"27402532\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct BMP-responsive cis-elements in SOST not fully mapped in osteocytes\", \"Differential downstream signaling for Sost vs Dkk1 partially characterized\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Double-knockout and class-selective LRP6 antibody experiments resolved that Sost-deficiency anabolism depends only partially on LRP5 but fully on Wnt1-class LRP6 signaling.\",\n      \"evidence\": \"Sost-/-;Lrp5-/- mice with anti-LRP6 antibodies, microCT and histomorphometry\",\n      \"pmids\": [\"23901037\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ligand source for Wnt1-class signaling in bone not defined\", \"Molecular reason for LRP6 dominance not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identifying Piezo1, PGE2/EP4-ERK, ER\\u03b2, periostin, and nitric oxide as mediators progressively mapped the mechanotransduction cascade that suppresses SOST in osteocytes.\",\n      \"evidence\": \"Pharmacological and genetic loss-of-function across osteocyte cell lines and loading/fluid-flow models\",\n      \"pmids\": [\"31708103\", \"21723865\", \"23362266\", \"19837663\", \"24322886\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How these inputs converge on the MEF2 enhancer not integrated\", \"Relative contribution of each pathway in vivo unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defining the LRP6-dependent, N-cadherin-modulated PTH-PTH1R axis showed how PTH-induced SOST suppression is mechanistically wired in osteocytes.\",\n      \"evidence\": \"Osteoblast/osteocyte-specific Lrp6 and Cdh2 knockouts with iPTH challenge and LRP6-PTHR1 co-IP\",\n      \"pmids\": [\"25847683\", \"27723935\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Precise step where LRP6 couples to MEF2/HDAC regulation not resolved\", \"Single-lab findings on N-cadherin modulation\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Promoter-level studies extended SOST regulation to additional transcription factors and epigenetic inputs (RUNX2, Sirt1/H3K9 deacetylation, HIF-1\\u03b1, DNA methylation, vitamin D).\",\n      \"evidence\": \"EMSA, ChIP, promoter-reporter, siRNA, and methylation analyses across osteosarcoma, osteocyte, and chondrocyte models\",\n      \"pmids\": [\"14739291\", \"21952235\", \"23776575\", \"26071314\", \"26690786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Many findings are single-lab and cell-line based\", \"Integration with the dominant downstream enhancer not established\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Functional analysis of secretion-defective mutants distinguished dominant-negative craniodiaphyseal dysplasia mutations from recessive loss-of-function alleles and established cystine-knot requirement for secretion and LRP5 binding.\",\n      \"evidence\": \"Transfection secretion assays, ER-retention, LRP5 binding and Wnt reporter assays for signal-peptide and Cys167Arg mutants\",\n      \"pmids\": [\"21221996\", \"20583295\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Dominant-negative mechanism on wild-type secretion not fully characterized\", \"Single-study functional data\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Cell-type-specific deletions established sclerostin's paracrine, non-endocrine mode of action and identified multiple osteoblast-lineage sources contributing to the bone microenvironment.\",\n      \"evidence\": \"Four Cre-driven conditional Sost knockouts with microCT, DXA, histomorphometry, and B-cell FACS\",\n      \"pmids\": [\"29750826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of paracrine vs endocrine restriction not defined\", \"B-cell phenotype mechanism not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identifying non-skeletal roles\\u2014limb digit patterning with Sostdc1, joint MMP regulation, and a STAT3 interaction in cancer\\u2014broadened SOST function beyond bone Wnt antagonism.\",\n      \"evidence\": \"Compound knockouts with Shh/Gli epistasis, PTOA transgenic/KO models, and SOST-STAT3 Co-IP with metastasis assays\",\n      \"pmids\": [\"23994639\", \"29377313\", \"36581888\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"STAT3 interaction rests on a single-lab Co-IP in cancer context\", \"Mechanistic depth of MMP and developmental roles limited\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the diverse upstream regulators (mechanical, hormonal, BMP, epigenetic) converge on the MEF2-dependent downstream enhancer to set quantitative SOST output remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No integrated model linking signaling inputs to enhancer occupancy\", \"Structural basis of sclerostin-LRP binding not in corpus\", \"Non-bone functions need independent validation\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 3, 18]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 16, 35]},\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 18]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [34, 35]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 16]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"LRP5\", \"LRP6\", \"STAT3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"tie","faith_supported":8,"faith_total":8,"faith_pct":100.0}}